Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkins lymphomas (NHL) and certain autoimmune diseases[1].
Molecular Weight:
(146.58 kDa)
Purity:
99.53
CAS Number:
[205923-57-5]
Target:
CD22
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted